more resources

 

  • Blind Spots Podcast: Exploring What We Cannot See

    Luminous: A Series About Psychedelics from 'To The Best Of Our Knowledge'

    Back from the Abyss: Psychiatry in Short Stories

    Psychedelics Today

    • How to Change Your Mind: What the New Science of Psychedelics Teaches Us About Consciousness, Dying, Addiction, Depression, and Transcendence by Michael Pollan

    • Psychedelic Medicine: The Healing Powers of LSD, MDMA, Psilocybin, and Ayahuasca by Dr. Richard Louis Miller

    • The Ketamine Papers: Science, Therapy, and Transformation Edited by Phil Wolfson M.D., Glenn Hartelius Ph.D.

    • Psychedelic Mysteries of the Feminine: Creativity, Ecstasy, and Healing Edited by by Maria Papaspyrou, Chiara Baldini, and David Luke

  • Psychedelic Research and Training Institute (PRATI)

    Fluence

    Polaris Insight Center

    Naropa (certificate in psychedelic therapies)

  • The Spirit Pharmacist

  • Ketamine:

    • Dore, J., Turnipseed, B., Dwyer, S., Turnipseed, A., Andries, J., Ascani, G., Monnette, C., Huidekoper, A., Strauss, N., & Wolfson, P. (2019). Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and Outcomes in Three Large Practices Administering Ketamine with Psychotherapy. Journal of psychoactive drugs, 51(2), 189–198. https://doi.org/10.1080/02791072.2019.1587556

    • Walsh, Z., Mollaahmetoglu, O. M., Rootman, J., Golsof, S., Keeler, J., Marsh, B., Nutt, D. J., & Morgan, C. J. A. (2021). Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review. BJPsych open, 8(1), e19. https://doi.org/10.1192/bjo.2021.1061

    • Garel, N., Drury, J., Thibault Lévesque, J., Goyette, N., Lehmann, A., Looper, K., ... & Greenway, K. T. (2023). The Montreal model: an integrative biomedical-psychedelic approach to ketamine for severe treatment-resistant depression. Frontiers in Psychiatry, 14, 1268832.

    Psilocybin:

    • Haikazian, S., Chen-Li, D. C. J., Johnson, D. E., Fancy, F., Levinta, A., Husain, M. I., Mansur, R. B., McIntyre, R. S., & Rosenblat, J. D. (2023). Psilocybin-assisted therapy for depression: A systematic review and meta-analysis. Psychiatry research, 329, 115531. https://doi.org/10.1016/j.psychres.2023.115531

    MDMA:

    • Mitchell, J. M., Bogenschutz, M., Lilienstein, A., Harrison, C., Kleiman, S., Parker-Guilbert, K., Ot'alora G, M., Garas, W., Paleos, C., Gorman, I., Nicholas, C., Mithoefer, M., Carlin, S., Poulter, B., Mithoefer, A., Quevedo, S., Wells, G., Klaire, S. S., van der Kolk, B., Tzarfaty, K., … Doblin, R. (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature medicine, 27(6), 1025–1033. https://doi.org/10.1038/s41591-021-01336-3

    • Geller, J., & Shannon, S. (2024). MDMA for PTSD and beyond: A new paradigm brings hope. Frontiers in Human Neuroscience, 18, 1475013. https://doi.org/10.3389/fnhum.2024.1475013

    • Geller, J., & Whitney, E. (2024). Therapeutic potential of MDMA- and psychedelic-assisted psychotherapy for adolescent depression and trauma. Current Psychiatry Reports, 26(2), 34–45. https://doi.org/10.1007/s11920-024-01577-2

    • Aday, J. S., McAfee, J., Conroy, D. A., Hosanagar, A., Tarnal, V., Weston, C., Scott, K., Horowitz, D., Geller, J., Harte, S. E., Pouyan, N., Glynos, N. G., Baker, A. K., Guss, J., Davis, A. K., Burgess, H. J., Mashour, G. A., Clauw, D. J., & Boehnke, K. F. (2025). Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: An open-label pilot clinical trial. Frontiers in Pain Research, 6, 1527783. https://doi.org/10.3389/fpain.2025.1527783

    • Pfeiffer, P. N., Hosanagar, A., Geller, J., et al. (2024). Ketamine helped many severely depressed veterans, study shows. University of Michigan Department of Psychiatry News. https://medicine.umich.edu/dept/psychiatry/news/archive/202401/ketamine-helped-many-severely-depressed-veterans-study-shows

    • Geller, J., Glynos, N. G., Lemmen, A., Pacilio, R., Kruger, D. J., & Hosanagar, A. (2024). Trainees unprepared for advances in psychedelic medicine: A survey study. Journal of Psychoactive Drugs, 1–8. https://doi.org/10.1080/02791072.2024.2341795

    • Geller, J., Keith, K. M., Froehlich, A., Arfken, C., Oxley, M., & Mischel, N. (2023). Response to ketamine treatment for major depressive disorder not associated with number of psychiatric comorbidities. Journal of Affective Disorders Reports, 5, 100123. https://doi.org/10.1016/j.jadr.2023.100123

    • Pacilio, R. M., & Geller, J. A. (2025). Persistent psychosis associated with intravenous ketamine in a patient using cannabis: A case report and literature review. Journal of Clinical Psychopharmacology. Advance online publication. https://doi.org/10.1097/JCP.0000000000001995

    • Keith, K. M., Geller, J., Froehlich, A., Arfken, C., Oxley, M., & Mischel, N. (2022). Vital sign changes during intravenous ketamine infusions for depression: An exploratory study of prognostic indications. Journal of Clinical Psychopharmacology, 42(3), 254–259. https://doi.org/10.1097/JCP.0000000000001542